title: [Clinical observation on acupuncture combined with microorganism pharmaceutical preparations for treatment of irritable bowel syndrome of constipation type].
abstract: OBJECTIVE
  To explore the best program for treatment of irritable bowel syndrome (IBS) of constipation type.
  
  
  METHODS
  Ninety-five cases of IBS were randomly divided into 3 groups. Group A (n = 30) were treated by acupuncture combined with microorganism pharmaceutical preparations, group B (n = 35) by oral administration of medicine for loosening the bowel to relieve constipation plus microorganism pharmaceutical preparations, and group C (n = 30) by simple acupuncture.
  
  
  RESULTS
  The total effective rates were 90.0%, 77.2% and 66.7%, in the group A, B and C, respectively, with a very significant differences as the group A compared with those in the groups B, C (P < 0.01), and with no significant difference as the group B compared with that of the group C (P > 0. 05). The intestinal available bacteria, bilidobacteria and lactobacillus, increased and enteric bacilli decreased in varying degrees in the 3 groups.
  
  
  CONCLUSIONS
  Acupuncture combined with microorganism pharmaceutical preparations has a better therapeutic effect on irritable bowel syndrome of constipation type.
authors.affiliation: Internal Department, The Second People' s Hospital of Shenzhen, Guangdong 518035, China.
authors.forename: Ze-rong
authors.initials: ZR
authors.lastname: Long
authors.forename: Cun-hai
authors.initials: CH
authors.lastname: Yu
authors.forename: Yu
authors.initials: Y
authors.lastname: Yang
authors.forename: Huai-ning
authors.initials: HN
authors.lastname: Wang
authors.forename: Xiao-xia
authors.initials: XX
authors.lastname: Chi
mesh_terms: D015670:Acupuncture Therapy; D000328:Adult; D003131:Combined Modality Therapy; D003248:Constipation / Q000628:therapy*; D005260:Female; D006801:Humans; D007422:Intestines / Q000382:microbiology; D043183:Irritable Bowel Syndrome / Q000382:microbiology / Q000628:therapy*; D008297:Male; D019936:Probiotics / Q000627:therapeutic use*